SWOG clinical trial number
CTSU/EA2201
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Open
Phase
II
Abbreviated Title
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Status Notes
May Thet Cho, MD SWOG Champion
Activated
05/13/2021
Research committees
Gastrointestinal Cancer
Treatment
Ipilimumab
Nivolumab
Eligibility Criteria Expand/Collapse
SWOG is participating in this study through the Cancer Trials Support Unity (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA2201
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
05/13/2021
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA2192
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Research Committee(s)
Gastrointestinal Cancer
Activated
04/29/2021
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA2197
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Research Committee(s)
Gastrointestinal Cancer
Activated
12/22/2020
Open
Phase
II-III